Nanoformulations to fight respiratory infections
Official title: Nanoformulations for Respiratory Infections
Funded at James a. Haley VA Medical Center · NIH-11206944 · Data updated 2026-11-12
A researcher team is developing a nasal therapy using tiny lipid particles and DNA to block viruses like SARS-CoV-2 and RSV from spreading in the nose and lungs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | James a. Haley VA Medical Center NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2027 |
| NIH project number | 5I01BX006456-02 |
| Project ID | NIH-11206944 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for severe respiratory viral infections or those with recurrent infections, pending safety and efficacy data.
✕Less likely to help
If the therapy is not effective or safe, patients may not experience any benefit and could face risks from nasal treatment.
What this research studies
This project aims to create a broad-spectrum intranasal treatment that can prevent or slow respiratory viruses from taking hold in the airways. The approach uses a liposomal system with alpha-linolenic acid and acetate to trigger antiviral pathways and block viral replication, with an added slow-release DNA component to produce protective RNAs. The work is designed to be tested in preclinical or early-stage settings to assess how well this formulation prevents infection and dampens dangerous immune responses. If successful, this could lead to new options for protecting people during outbreaks of coronaviruses and other seasonal viruses.
Why it matters
Potential benefit: If successful, patients could have a new nasal therapy to reduce viral infections and severity during outbreaks.
How similar studies have gone: Similar liposomal antiviral approaches have shown promise in early studies, but this specific formulation is novel.
Where this research is happening
-
James a. Haley VA Medical Center
Tampa, United States Active
Researchers
- Principal investigator: Mohapatra, Shyam S — James a. Haley VA Medical Center
- Study coordinator: Mohapatra, Shyam S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.